AACR-iCML 2024
Jun 19 - 22, 2024 | Philadelphia, PA
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
Trial in Progress: Phase 1 Study of ARV-393, a PROteolysis TArgeting Chimera (PROTAC) B-Cell Lymphoma 6 Degrader, in Advanced Non-Hodgkin LymphomaPF Caimi et al.